Keltic Pharma Therapeutics
@keltic-pharma.com
In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.
Keltic Pharma Therapeutics's Company Logos
Keltic Pharma Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#183B1A
Celtic
24, 59, 26
123, 42, 16
59, 0, 56, 77
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#0C4534
Bottle Green
12, 69, 52
162, 70, 16
83, 0, 25, 73
About Keltic Pharma Therapeutics
KELTIC Pharma is a world-class leader in fundamental biology and drug discovery chemistry. Our mission is to unlock the full potential of the world's most successful drug targets, leading to transformative innovations in patient treatment. We are focused on developing groundbreaking malaria treatments, with a curative, transmission-blocking, and prophylactic first-in-class malaria treatment targeting Plasmodium falciparum protein kinase PfCLK3.
Our innovative peptide-to-small molecule (PEP-SMOL) drug discovery platform enables us to unlock hard-to-target G-Protein-Coupled-Receptors (GPCRs), thus generating next-generation anti-malarials and clinical candidates against GPCRs to treat unmet medical needs. KELTIC Pharma is led by a world-class team of experts, including the founders who have extensive experience in the malaria field and GPCR research. By working with partner organizations, we are committed to improving patient outcomes and revolutionizing drug discovery technology to create a pipeline of innovative drug targets.
Join us in leading the way in malaria drug discovery and unlocking the potential of high-value GPCR drug targets. Contact us for more information
Company type
Public Company
Year founded
2020
Company size
11-50 employees
